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Barresi,’’ University of Messina, Messina, ItalyObjective: To assess the impact of endometrial scratch injury (ESI) on the outcomes of intrauterine insemination (IUI) stimulated cycles.
Design: Systematic review and meta-analysis.
Setting: Not applicable.
Patient(s): Infertile women undergoing one or more IUI stimulated cycles.
Intervention(s): Randomized controlled trials (RCTs) were identiﬁed by searching electronic databases. We included RCTs
comparing ESI (i.e., intervention group) during the course of IUI stimulated cycle (C-ESI) or during the menstrual cycle preceding
IUI treatment (P-ESI) with controls (no endometrial scratch). The summary measures were reported as odds ratio (OR) with 95%
conﬁdence-interval (CI).
Main OutcomeMeasure(s): Clinical pregnancy rate, ongoing pregnancy rate, multiple pregnancy rate, ectopic pregnancy rate, miscar-
riage rate.
Result(s): Eight trials were included in the meta-analysis, comprising a total of 1,871 IUI cycles. Endometrial scratch injury was
associated with a higher clinical pregnancy rate (OR 2.27) and ongoing pregnancy rate (OR 2.04) in comparison with the controls.
No higher risk of multiple pregnancy (OR 1.09), miscarriage (OR 0.80), or ectopic pregnancy (OR 0.82) was observed in patients
receiving ESI. Subgroup analysis based on ESI timing showed higher clinical pregnancy rate (OR 2.57) and ongoing pregnancy rate
(OR 2.27) in patients receiving C-ESI and no advantage in patients receiving P-ESI.
Conclusion(s): Available data suggest that ESI performed once, preferably during the follicular phase of the same cycle of IUI with
ﬂexible aspiration catheters, may improve clinical pregnancy and ongoing pregnancy rates in IUI cycles. Endometrial scratch injury
does not appear to increase the risk of multiple pregnancy, miscarriage, or ectopic pregnancy. (Fertil Steril 2018;109:84–96.
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Fertility and Sterility®I ntrauterine insemination (IUI) is currently considered theﬁrst line of treatment for subfertile couples because of itslow cost, psychological burden, and easy access (1, 2). It is
indicated to treat a variety of reproductive issues, including
unexplained subfertility, minimal to mild endometriosis, male
subfertility, and physical disability/psychosexual problems (3,
4). However, despite continuing investigations of ovarian
stimulation protocols (1, 5) and luteal phase support (1, 6),
pregnancy rates with IUI are still limited and quite variable,
ranging from 10% to 25% (7). Investigators have ascribed
these mixed results to defects in the implantation process (2, 8).
Endometrial scratch injury (ESI) is a technique that has
been proposed to improve implantation in women undergo-
ing treatment with assisted reproduction technology (ART)
(9–11). Endometrial scratch injury consists of a voluntary
endometrial trauma aimed at inducing an acute
inﬂammatory process, prompting the local release of
growth factors and proinﬂammatory cytokines (2, 8). The
trauma can be achieved simply by a Pipelle biopsy, curette,
or hysteroscope at low cost and with no need of analgesia
or anaesthesia (9, 12, 13).
Presently ESI is offered in women undergoing in vitro
fertilization (IVF) cycles (9, 10). Its application in patients
undergoing IUI is far less common and less extensively
documented (14). The only systematic review performed on
this topic (14), which summarized evidence up to October
2015, included women who were both undergoing IUI and
attempting to conceive via sexual intercourse, and found
poor evidence quality in support of ESI use. Indeed, the
results provided by Lensen et al. (14) reﬂected a high risk of
bias due to the heterogeneity among their populations and
poor methodological quality of the studies.
From October 2015 to date, several new randomized
controlled trials (RCTs) have evaluated ESI before IUI (2, 8,
15, 16). Because the cumulative number of patients and
studies almost doubled over this span of time, a new
summary of evidence is needed. Our updated, systematic
review and meta-analysis assessed the impact of ESI on the
outcomes of IUI stimulated cycles.MATERIALS AND METHODS
Study Design
We conducted a systematic review and meta-analysis of all
RCTs investigating the impact of endometrial scratch injury
on IUI outcomes. The review was reported following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines (17). As this study was
a systematic review and meta-analysis of published data,
formal ethics approval was not required.Inclusion Criteria
The included studies were limited to RCTs with results
published in English. The populations comprised infertile
women undergoing one or more IUI stimulated cycles. The
intervention under study was endometrial injury during the
course of an IUI stimulated cycle or during the menstrual cy-
cle preceding the IUI treatment. Infertile women undergoingVOL. 109 NO. 1 / JANUARY 2018IUI stimulated cycles but not receiving an endometrial injury
composed the control groups.Outcomes
Our primary goal was to compare the outcomes of IUI stimu-
lated cycles in patients receiving ESI with those of patients
not receiving the intervention (controls). The secondary
goal was to evaluate the inﬂuence of ESI timing on IUI
outcomes by cross-matching patients receiving ESI concom-
itant to the IUI cycle (C-ESI) with those receiving ESI in the
cycle preceding IUI (P-ESI) versus control patients who
received no ESI. We also evaluated pain and potential compli-
cations associated with ESI.
The outcome measures were deﬁned as follows. Clinical
pregnancy rate (CPR) per cycle was deﬁned as the presence
of a gestational sac on transvaginal ultrasound or other deﬁn-
itive clinical signs. Ongoing pregnancy rate (OPR) per cycle
was deﬁned as the presence of a living intrauterine fetus on
transvaginal ultrasound at 12 weeks' gestation. Multiple
pregnancies (MPR) per cycle were deﬁned as the presence of
more than one gestational sac on transvaginal ultrasound.
Miscarriage rate (MR) per clinical pregnancy was deﬁned as
fetal loss before 20 weeks' gestation. Ectopic pregnancy rate
(EPR) per clinical pregnancy was deﬁned as a pregnancy
implanting outside the uterus.Search Strategy
A systematic literature search was conducted on the
electronic databases PubMed, Embase, ScienceDirect, the
Cochrane library, Clinicaltrials.gov, the Cochrane Central
Register of Controlled Trials, the EU Clinical Trials Register,
and World Health Organization International Clinical Trials
Registry Platform up to July 18, 2017 (without date restric-
tion). The search used speciﬁc key words and database index-
ing terminology. The key search terms included endometrial
injury OR endometrial scratch OR endometrial biopsy OR
endometrial sampling [Mesh/Emtree] AND insemination OR
IUI.Study Selection and Data Extraction
Two authors (A.V., M.N.) independently screened the titles
and abstracts of the studies obtained via our search strategy,
and each independently obtained and assessed the text of the
potentially relevant studies for inclusion in the review. A
manual search of the reference lists of the retrieved studies
and available review articles was successively performed to
avoid missing any relevant publications. The same authors
(A.V., M.N.) also independently extracted data from the
studies about their features and included populations
(country, time when the study was performed, number of par-
ticipants, and main inclusion criteria), ovarian stimulation
cycles (drugs employed for ovarian stimulation, timing of
ovulation induction), and IUI outcomes. If more than one
study was published for the same cohort with identical end
points, the report containing the most comprehensive infor-
mation on the population was included to avoid overlapping
populations. One other author (C.S.) independently reviewed85
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONthe selection and data extraction processes. The results were
compared, and any disagreements were discussed and
resolved by consensus.
Risk of Bias
Two reviewers (A.M., M.N.) independently judged the
methodological quality of the studies included in this
meta-analysis using the Cochrane Collaboration's tool for
bias risk assessment (18). Their recommended approach for
assessing the risk of bias in studies is a two-part tool that ad-
dresses seven speciﬁc domains: sequence generation and
allocation concealment (selection bias), blinding of partici-
pants and providers (performance bias), blinding of outcome
assessor (detection bias), incomplete outcome data (attrition
bias), selective outcome reporting (reporting bias), and other
sources of bias (other bias). None of the included studies was
blinded to patients, clinicians, or assessors, but this factor
was unlikely to generate bias because of the impossibility
of blinding ESI. Performance bias was considered as low
for all the included studies, and detection bias was evaluated
according to the presence or absence of systematic differ-
ences between groups potentially affecting the outcomes
determined by the assessors (i.e., heterogeneity in ovarian
stimulation before IUI). For the estimation of reporting
bias, we evaluated the study protocols, when available.
When they were not available, we compared the end points
of each study with the results provided by the investigators
to identify any possible inconsistencies. For the ‘‘other bias’’
domain, all studies without a recorded protocol in national
or international registry were considered at high risk of
bias. Any discrepancies in an author's judgment were
referred to a third reviewer (A.D.S.S.) and were resolved by
consensus.Statistical Analysis
The statistical analysis was performed using Review Manager
version 5.2 (Cochrane Collaboration, Software Update).
Dichotomous variables were analyzed using odds ratio (OR)
and 95% conﬁdence interval (95% CI). P< .05 was considered
statistically signiﬁcant. To assess heterogeneity, the I2 statis-
tic was used. (The value of I2 describes the percentage of vari-
ability in point estimates that is due to heterogeneity rather
than sampling error.) We considered the degree of heteroge-
neity to be low when I2 was <30%, moderate if between
30% and 50%, and high if >50%. When the heterogeneity
was moderate or high, we reported both the random and the
ﬁxed outcomes to emphasize the role of heterogeneity among
the studies. When the heterogeneity was low, the ﬁxed and
the random models gave similar values, and the results were
reported only in a ﬁxed effects model using the more conser-
vative value.
In addition, the inﬂuence of individual studies on the
overall results was explored by serially excluding each study
and different study subgroups (according to the authors’
methodological quality judgment) in a sensitivity analysis.
Moreover, a subgroup analysis was performed to evaluate
the speciﬁc inﬂuence of different ESI timings on the pooled
OR.86We aimed to assess publication bias (related to size of the
trials) with the use of a funnel plot (a plot of the effect estimate
from each study against the standard error) if at least 10
studies were included in the meta-analysis, according to Co-
chrane Handbook's recommendations (Cochrane Handbook
10.4.3.1, ‘‘Recommendations on Testing for Funnel Plot
Asymmetry’’). Nevertheless, not enough studies were included
in the ﬁnal meta-analysis (eight studies).Grading of Evidence
Two authors (A.V. and M.N.) independently assessed the body
of evidence for the primary outcome of the meta-analysis
using GRADE (Grading of Recommendations Assessment
Development and Evaluation Working Group) (19)
methodology. (The GRADE Pro software is available at
https://gradepro.org/.) The GRADE criteria allow the evalua-
tion of certainty of evidence in terms of study design, risk
of bias, indirectness, inconsistency, imprecision, large effect
size, plausible confounding, dose response gradient, and pub-
lication bias. We did not evaluate the dose response gradient
(intervention was a dichotomous variable). We aimed to
exclude outlier studies from the ﬁnal assessment of quality
of evidence if they signiﬁcantly reduced the heterogeneity
of the analyzed populations (but without producing weak-
ening of the ﬁnal sample size or alterations in conclusive re-
sults). However, the degree of heterogeneity was extremely
low, so no studies were excluded. Disagreements between re-
viewers were resolved by discussion and adjudication of a
third reviewer (A.D.S.S.).
RESULTS
Study Selection
The literature search, based on our predeﬁned key search
items, identiﬁed 3,554 publications after removing dupli-
cates. The titles of these publications were screened, resulting
in 96 studies considered potentially eligible to be included in
the review. Of the total of relevant publications identiﬁed, 83
studies were excluded after examination of their abstracts,
and 13 studies were further evaluated. After the evaluation
of the full publication text, ﬁve RCTs were additionally
excluded: one study comparing the effects of ofﬁce hysteros-
copy with endometrial scratch versus ofﬁce hysteroscopy on
IUI outcomes (13), two clinical trials that were ongoing at the
time of data collection (20, 21), and two additional studies
deemed ineligible for only investigating the effect of ESI on
natural conception (22, 23). In the end, a total of eight
studies (2,8,15,16,24–27) were included in the present meta-
analysis after applying our inclusion criteria (see
Supplemental Fig. 1, available online).Included Studies
The eight studies included comprised a total of 1,871 IUI cy-
cles and 1,523 participants, with sample sizes (of IUI cycles)
ranging from 144 cycles (2) to 415 cycles (27). Patients
received ESI in 998 IUI cycles, and ESI was not performed
in 873 IUI cycles. The total number of cycles with C-ESI
was 747, and the number with P-ESI was 251. Five studiesVOL. 109 NO. 1 / JANUARY 2018
TABLE 1
Endometrial scratch injury in intrauterine insemination: general features of the studies.
Study Country Period Participants
Main inclusion
criteria
Ovarian
stimulation
Intervention and
timing Controls Outcomes
Abdelhamid,
2013 (24)
United
Arab
Emirates
03/2010–03/2012 150 women
undergoing
IUI
Unexplained
infertility
Age 22–35
y
Semen count
not less than
15 mil/mL,
motility
Grade a þ b
not less than
40% before
wash
Letrozole,
2.5 mg/d
on days
3–7 of
menstrual
cycle, then
rFSH, 75 IU
R-hCG (250 mg)
at follicle size
18–19 mm
Tao brush
endometrial
sampling
Group A (n¼ 50): on
days 8–9 of same
cycle
Group B (n ¼ 50): on
days 8–9 of the
cycle preceding IUI
Group C
(n ¼ 50): no
intervention
CPR, MPR
Zarei et al.,
2014 (26)
[IRCT201207
0810210N1]a
Iran 01/2011–05/2012 146 women
undergoing
IUI (total of
231 IUI cycles)
Dropout of two
women in
group A
Unexplained
infertility
Age 18–40 y
Mild male factor
infertility (semen
count between
5–15 mil/mL,
total motility
not less than
40%)
Mild
endometriosis
CC, 100 mg/d
on days
5–9 of
menstrual
cycle,
then rFSH,
100 IU
U-hCG
(10,000
IU) when
serum E2
level <1,500
pg/mL
Novak curette biopsy
Group A (n ¼ 72; IUI
cycles ¼ 126): on
days
6–8 of the cycle
preceding IUI
Group B
(n ¼ 72;
105 IUI
cycles): no
intervention
CPP, OPR,
MR, MPR
Maged et al.,
2016 (27)
Egypt 01/2010–01/2015 146 women
undergoing
IUI
Unexplained
infertility
Age <40 y
FSH level%12
mIU/mL
At least 1 patent
tube
Normal semen
analysis
(>20 mil/mL,
>50%
total motility,
>30%
normal
forms
CC, 100 mg/d
on days
3–7 of
menstrual
cycle,
then hMG,
150 IU
U-hCG (5,000
IU) when
>2 follicles
atR17 mm
or urinary LH
surge
No. 8 neonatal
feeding tube
Group A (n ¼ 77; IUI
cycles ¼ 200): 24–
36 h before IUI
Group B
(n ¼ 77; 215
IUI cycles):
no intervention
CPR, MR,
EPR, MPR
Wadhwa et al.,
2015 (25)
[CTRI/2013/04/
003521]a
India 08/2012–03/2014 251 women
undergoing
IUI
Dropout of 11
women in
Age 18–38 y
At least 1
patent
tube
Mild male
CC or CC þ hCG
or CC þ hCG
þ hMG
Endometrial
aspiration cannula
Group A (n ¼ 75):
before day 6 of
same cycle
Group B
(n ¼ 75): no
intervention
CPR, MR,
MPR
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TABLE 1
Continued.
Study Country Period Participants
Main inclusion
criteria
Ovarian
stimulation
Intervention and
timing Controls Outcomes
group A
Dropout of
11 women
in group B
factor
infertility
Group B (n ¼ 75): on
days 19–24 of
cycle preceding IUI
Baha Eldin et al.,
2016 (16)
[NCT02542280]a
Egypt 07/2013–08/2015 360 women
undergoing
IUI
Dropout of
11 þ 5
women in
group A
Age 20–35 y
At least 1
patent
tube
Mild male
factor
infertility
CC, 100 mg/d
on days 2–6
of menstrual
cycles, þ hMG
75 IU (from day
3/7 on alternating
days)
U-hCG (5,000 IU) at
follicle sizeR18
mm
Pipelle
Group A (n¼ 169): on
days 5–7 of same
cycle
Group B
(n ¼ 175): no
intervention
CPR
Soliman and Harira,
2017 (8)
Egypt 03/2013–05/2015 233 women
undergoing
IUI
Dropout of
7 women
Unexplained
infertility
Mild male
factor
infertility
CC, 100 mg/d on days
2–6 of menstrual
cycle, then hMG,
75 IU
U-hCG (10,000 IU)
for ovulation
triggering
Embryo mucus
aspiration catheter
Group A (n¼ 106): on
day 7 of same
cycle
Group B
(n ¼ 106): no
intervention
CPR, OPR, MR
Ashraﬁ et al., 2017
(15)
[IRCT2015072711
41N19]a
Iran 01/2013–01/2014 169 women
undergoing
IUI
Dropout of
19 women
R2 previous
IUI failures
Age <40 y
Normal uterine
anatomy and
HSG result
Normal semen
analysis
CC, 100 mg/d,
or letrozole,
2.5 mg/d, on
days 3–7 of
menstrual cycle,
and hMG,
75–150 IU
(from days 6 to 8)
U-hCG (10,000 IU)
at follicle size
R18 mm
Pipelle
Group A (n ¼ 75): on
days 8–9 of same
cycle
Group B
(n ¼ 75): no
intervention
CPR, MR
Goel et al., 2017 (2)
[CTRI/2015/12/00
6419]a
India 07/2014–07/2016 144 women
undergoing
IUI
Age 21–35 y
BMI 18.5–29.9
kg/m2
Euthyroid state
FSH <10 mIU/mL
At least 1
patent tube
CC, 50 mg/d on days
2–6 of menstrual
cycle
U-hCG (5,000 IU) at
follicle size
R18 mm
Karman cannula no. 4
Group A (n ¼ 72): on
day 8 of same
cycle
Group B
(n ¼ 72): no
intervention
CPR, OPR, MR, EPR
Note: BMI ¼ body mass index; CC ¼ clomiphene citrate; CPR ¼ clinical pregnancy rate; E2 ¼ estradiol; EPR ¼ ectopic pregnancy rate; FSH ¼ follicle-stimulating hormone; hMG ¼ human menopausal gonadotropin; HSG ¼ hysterosalpingography; IUI ¼ intrauterine
insemination; LH¼ luteinizing hormone;MPR¼multiple pregnancy rate; MR¼miscarriage rate; OPR¼ ongoing pregnancy rate; rFSH¼ recombinant follicle-stimulating hormone; R-hCG¼ recombinant human chorionic gonadotropin; U-hCG¼ urinary human chorionic
gonadotropin.
a Registered trial with identiﬁcation code.
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FIGURE 1
Endometrial scratch versus no intervention. (A) Clinical pregnancy rate. (B) Ongoing pregnancy rate. (C) Multiple pregnancy rate. (D) Miscarriage
rate. (E) Ectopic pregnancy rate.
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ORIGINAL ARTICLE: ASSISTED REPRODUCTION(2, 8, 15, 16, 27) compared C-ESI with no intervention, one
study (26) compared P-ESI with no intervention, and two
studies (24, 25) compared C-ESI, P-ESI, and no treatment. A
summary of the main characteristics of the included studies
is available in Table 1.
Types of patients. Maged et al. (27) enrolled patients with
primary or secondary unexplained infertility. Zarei et al.
(26) recruited couples with unexplained infertility, mild
male factor infertility, or mild endometriosis. In three studies
(15, 24, 25) the couples had unexplained infertility, mild male
factor infertility, or ovulatory dysfunction. Three studies (2, 8,
16) enrolled couples with mild male factor infertility or
unexplained infertility.
Inﬁve studies (8, 15, 16, 24, 25) the analysis was conducted
on a single IUI cycle attempt. In three studies (2, 26, 27) the
patients underwent up to three IUI attempts. In Soliman and
Harira (8) and Ashraﬁ et al. (15) all patients recruited had
one or at least two previous IUI failures, respectively.
Types of IUI cycles. For follicle recruitment, all the studies
used a 5-day regimen of either clomiphene citrate at
100 mg/day, except Goel et al. (2) who used 50 mg/day, or le-
trozole at 2.5 mg/day in the early follicular phase (mainly
from days 2 to 6 or days 3 to 7). Only Bahaa Eldin et al. (16)
combined clomiphene citrate with human menopausal
gonadotropin (hMG) at 75 IU on alternating days. After prim-
ing with clomiphene citrate or letrozole, ovarian stimulation
was continued with the administration (single, double, or
daily) of hMG or recombinant follicle-stimulating hormone
(FSH), except in two studies: Goel et al. (2) administered
only clomiphene citrate before ovulation induction, and
Wadhwa et al. (25) administered only clomiphene citrate to
a subgroup of patients.
Ovulation induction was triggered with 5,000–10,000 IU
of urinary human chorionic gonadotropin (U-hCG) in all
studies, except for a subgroup in Wadhwa et al. (25), on the
basis of estradiol levels (>1,500 pg/mL) (26), urinary luteiniz-
ing hormone (LH) surge (27), or transvaginal ultrasound
showing preovulatory follicles (2, 8, 15, 16, 24, 25).
Type of intervention. In all the studies ESI was performed
once. The majority of trials used a ﬂexible aspiration catheter
(Pipelle, neonatal feeding tube, Endocell aspiration cannula,
embryo mucus aspiration catheter, or Karman cannula),
except Abdelhamid (24), who employed a cytobrush (a Tao
brush), and Zarei et al. (26) who used a Novak curette (to
perform a small biopsy on the anterior and posterior uterine
wall).
For timing, C-ESI was performed between days 5 and 9 in
six studies (2, 8, 15, 16, 24, 25). Maged et al. (27) performed C-
ESI 24 to 36 hours before IUI. For P-ESI, two studies (24, 26)
performed the intervention in the interval between days 6 and
9. Wadhwa et al. (25) performed the intervention on days 19
to 24 (of the cycle preceding IUI).
Assessment of the Risk of Study Bias
Selection bias. All of the studies used an adequate method of
random sequence generation, except for Goel et al. (2) and
Maged et al. (27), whose studies were judged at unclear risk90of selection bias because they did not provide their randomi-
zation information. Moreover, in three studies (2, 8, 26) the
method of allocation concealment was not reported, so they
were judged to be at unclear risk of selection bias. The
remaining studies (15, 16, 24, 25, 27) were considered at
low risk of bias for this domain.
Performance bias. Blinding of personnel and participants
was not possible for the types of intervention performed, so
performance bias was unlikely to inﬂuence the outcomes
evaluated. Nevertheless, all studies were judged at low risk
of bias.
Detection bias. Two studies (8, 25) were considered at high risk
or unclear risk of detection bias, respectively, due to the
heterogeneity in the ovarian stimulation protocols in the study
population and because of concerns about their calculation of
MR (by subtracting biochemical pregnancies from clinical
pregnancies). Another study (27) was considered to be at high
risk of bias due to the heterogeneity of results between the
ﬁrst and second IUI attempts in terms of CPR and OPR (no
beneﬁcial effect at the ﬁrst attempt, and large beneﬁcial effect
at the second attempt). One additional study (16) was judged
to be at high risk of bias due to the inclusion of polycystic
ovary syndrome patients, potentially affecting the comparison
between, groups. The remaining studies (2, 15, 24, 26) were
judged to be at low risk of bias.
Attrition bias. Two studies (8, 24) were judged to be at high
risk of attrition bias because of missing data outcomes.
Abdelhamid (24) did not report the mean b-human
chorionic gonadotropin values, and Soliman and Harira (8)
had 15 patients in the ESI group drop out. The other studies
were at low risk of attrition bias.
Reporting bias. Two studies (24, 25) were judged at high risk
of bias for selective data reporting. Abdelhamid (24) reported
data about clinical and multiple pregnancies, even stating
that patients were evaluated until the pregnancy test.
Wadhwa et al. (25) did not report the precise number of
patients who received different ovarian stimulation protocols.
The other studies (2, 8, 15, 16, 26, 27) were considered at low
risk of reporting bias.
Other bias. The absence of a registered protocol in agreement
with the study's performance was considered an additional
source of bias. For three studies (8, 24, 27) a protocol
registration was not available. For the remaining ﬁve studies
(2, 15, 16, 25, 26) a protocol registration was found in
international/national registers (Supplemental Fig. 2, available
online).Effects of Intervention
ESI versus no intervention. For CPR, the analysis involved a
total number of 1,871 IUI cycles (n¼ 998with ESI, and n¼ 873
with no intervention) from eight studies (2,8,15,16,24–27), with
282 clinical pregnancies recorded (n ¼ 199 in patients
receiving ESI, and n ¼ 83 in controls). The cumulative CPR
was 15.07%. The overall results statistically signiﬁcantly
favored ESI (OR 2.27; 95% CI, 1.71–3.00; P< .00001), with
no heterogeneity among studies (I2 ¼ 0) (Fig. 1A).VOL. 109 NO. 1 / JANUARY 2018
FIGURE 2
Endometrial scratch in the same cycle versus no intervention. (A) Clinical pregnancy rate. (B) Ongoing pregnancy rate.
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Fertility and Sterility®For OPR, three studies (2, 8, 26) with 587 participants
were included, of whom 304 were in the ESI group and 283
in control group. Cumulative number of ongoing
pregnancies was 84 (14.21%). The pooled OPR associated
with ESI result was considerably greater in comparison with
the control group (OR 2.04; 95% CI, 1.25–3.32; I2 ¼ 0;
P¼ .004) (see Fig. 1B).
The MPR of 1,021 IUI cycles (576 with ESI, and 445 with
no intervention) from four studies (24–27) was analyzed. The
total number of events was low (n ¼ 11, MPR 1.08%) with no
statistically signiﬁcant differences among the groups (OR
1.09; 95% CI, 0.35–3.45; I2 ¼ 0; P¼ .88) (see Fig. 1C).
For MR, 32 miscarriages among 199 clinical pregnancies
(from six studies: 2, 8, 15, 25–27) were observed (16.08%). No
difference emerged from comparisons of intervention and
control groups (OR 0.80; 95% CI, 0.35–1.82; I2 ¼ 0; P¼ .60)
(see Fig. 1D).
Two studies (2, 27) comparing C-ESI with no intervention
reported eight ectopic pregnancies. The EPRwas high (9.41%),
but no statistically signiﬁcant differences were found
between the intervention and control groups (OR 0.82; 95%
CI, 0.18–3.79; I2 ¼ 0; P¼ .80) (see Fig. 1E).
C-ESI versus no intervention. For CPR, the analysis involved
a total of 1,515 IUI cycles (n ¼ 747 with C-ESI, and n ¼ 768VOL. 109 NO. 1 / JANUARY 2018with no intervention) from seven studies (2, 8, 15, 16, 24, 25,
27). The cumulative CPR was 14.39%. The pooled CPR results
were statistically signiﬁcantly higher in the patients who
received C-ESI in comparison with the control group (OR
2.57; 95% CI, 1.89–3.51; I2 ¼ 0; P< .00001) (Fig. 2A).
For OPR, two studies (2, 8) with 356 participants were
included (n ¼ 176 in each group). The cumulative number
of ongoing pregnancies was 65 (cumulative OPR 18.26%).
Pooled OPR results were considerably greater in the ESI
group compared with controls (OR 2.27; 95% CI, 1.29–4.00,
I2 ¼ 0; P¼ .004) (see Fig. 2B).
For MPR, among 665 IUI cycles analyzed from three
studies (24, 25, 27), only seven events were observed (MPR
1.05%) with no statistically signiﬁcant differences found
the among groups (OR 2.29; 95% CI, 0.51–10.35; I2 ¼ 0;
P¼ .28).
The MR comprised 19 miscarriages among 164 clinical
pregnancies (11.58%) (from ﬁve studies: 2, 8, 15, 25, 27). No
difference emerged from comparisons of the intervention and
control groups (OR 1.17; 95% CI, 0.42–3.26; I2 ¼ 0; P¼ .76).
The EPR results were analogous to those reported in the
previous section.
P-ESI versus no intervention. For CPR, the analysis involved
a total of 481 IUI cycles (n¼ 251 with P-ESI, and n¼ 230with91
TABLE 2
Evidence proﬁle: endometrial scratch injury compared with no intervention in patients undergoing IUI cycles.
Outcomes
Anticipated absolute effects (95% CI)a
Relative effect
OR (95% CI)
No. of participants
(no. of RCTs)
Quality of the
evidence (GRADE)bRisk without ESI Risk with ESI
Clinical
pregnancy
rate
95/1,000 193/1,000 (152–240) 2.27 (1.71–3.00) 1,871 (8) 44, Lowc,d,e
Ongoing
pregnancy
rate
102/1,000 189/1,000 (125–275) 2.04 (1.25–3.32) 587 (3) 44, Lowd,e,f
Multiple
pregnancy
rate
9/1,000 10/1,000 (3–30) 1.09 (0.35–3.45) 1,021 (4) 44, Lowd,e,g
Miscarriage
rate
190/1,000 158/1,000 (76–300) 0.80 (0.35–1.82) 199 (6) 4, Very lowd,e,h,i
Ectopic
pregnancy
rate
107/1,000 90/1,000 (21–313) 0.82 (0.18–3.79) 85 (2) 4, Very lowd,e,j,k
Note: Question: Should ESI be used for patients undergoing IUI cycles? Patient or population: women undergoing IUI stimulated cycles. Intervention: ESI. Comparison: No ESI. CI ¼ conﬁdence
interval; ESI ¼ endometrial scratch injury; OR ¼ odds ratio; IUI ¼ intrauterine insemination; RCT ¼ randomized controlled trial.
a The risk in the intervention group (and its 95% conﬁdence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
b GRADEWorking Group grades of evidence. High quality:We are very conﬁdent that the true effect lies close to that of the estimate of the effect. Moderate quality:We aremoderately conﬁdent in
the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: Our conﬁdence in the effect estimate is limited;
the true effect may be substantially different from the estimate of the effect. Very low quality: We have very little conﬁdence in the effect estimate; the true effect is likely to be substantially different
from the estimate of effect.
c Four studies at unclear/high risk of selection bias, four studies at unclear/high risk of detection bias, two studies at high risk of attrition bias, two studies at high/unclear risk of reporting bias, and
three studies at high risk of other bias.
d Heterogeneity in endometrial scratch injury techniques/timing and in ovarian stimulation protocols.
e Possible small study effect.
f Three studies at unclear risk of selection bias, and one study at high risk of detection bias and other bias.
g Two studies at unclear risk of selection bias, one study at high risk of detection bias, one study at high risk of attrition bias, two studies at high/unclear risk of reporting bias, and two studies at high
risk of other bias.
h Four studies at unclear/high risk of selection bias, two studies at high risk of detection bias, one study at high risk of attrition bias, two studies at high/unclear risk of reporting bias, and two studies
at high risk of other bias.
i Small number of cases (n ¼ 199) and events (n ¼ 32).
j One study at unclear risk of selection bias, and one study at unclear risk of selection bias and high risk of other bias.
k Small number of cases (n ¼ 85) and events (n ¼ 8).
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONno intervention) from three studies (24–26). The cumulative
CPR was 16.63%. The pooled CPR results were higher in
patients who received P-ESI in comparison with the control
group, but were not statistically signiﬁcant with the random
effect model (I2 ¼ 37%; ﬁxed effect: OR 1.70; 95% CI, 1.04–
2.79; P¼ .04; random effect OR 1.75; 95% CI, 0.92–3.33;
P¼ .09) (Supplemental Fig. 3, available online).
For OPR, one study (26) with 231 participants was
included. The study showed no difference in OPR between
the P-ESI group and the controls (OR 1.47; 95% CI, 0.56–
3.89; P¼ .43).
For MPR, among 481 IUI cycles analyzed from three
studies (24–26), only ﬁve events were observed (MPR
1.04%) with no differences among the groups (I2 ¼ 37%;
ﬁxed effect OR 0.65; 95% CI, 0.13–3.30; P¼ .61; random
effect OR 0.69; 95% CI, 0.06–8.11; P¼ .76).
The MR comprised 13 miscarriages among 52 clinical
pregnancies (25%) (from two studies (25, 26). No differences
were observed between the intervention and control groups
(OR 0.54; 95% CI, 0.15–1.99, I2 ¼ 0; P¼ .35).
No data were available for comparing the EPR.
C-ESI versus P-ESI. For OPR and MPR, two studies (24, 25)
with 250 participants were analyzed (125 in each group).
No differences were found in pooled OPR (OR 1.04; 95% CI,
0.59–1.84; I2 ¼ 0; P¼ .88) (Supplemental Fig. 4, available
online) or MPR (OR 0.71; 95% CI, 0.14–3.68; I2 ¼ 0; P¼ .68)
between the two groups.92For MR, 4 miscarriages among 30 clinical pregnancies
(13.33%) were found by one study (25), with no difference
between the C-ESI and P-ESI groups (OR 0.33; 95% CI,
0.03–3.64; P¼ .60).
No data available for comparing CPR or EPR.
Sensitivity Analysis
Primary outcomes. The serial exclusion of each study from
the meta-analysis of ESI versus no intervention did not
produce statistically signiﬁcant changes in CPR (from OR
2.24; 95% CI, 1.69–2.98; to OR 2.56; 95% CI, 1.89–3.47),
with the exclusion of Ashraﬁ et al. (15) and Zarei et al.
(26). It produced no changes in OPR (from OR 1.91; 95%
CI, 1.04, 3.51; to OR 2.27; 95% CI, 1.29–4.00), with the
exclusion of Goel et al. (2) and Soliman and Harira (8). It
produced no changes in MPR (from OR 0.87; 95% CI,
0.23–3.36; to OR 1.96; 95% CI, 0.46–8.42), with the exclu-
sion of Maged et al. (27) and Zarei et al. (26). It produced no
changes in MR (from OR 0.70; 95% CI, 0.29–1.67; to OR
1.10; 95% CI, 0.39–3.06), with the exclusion of Wadhwa
et al. (25) and Zarei et al. (26). It produced no changes in
EPR (from OR 1.04; 95% CI, 0.17–6.54; to OR 0.45; 95%
CI, 0.03–7.73), with the exclusion of Maged et al. (27) and
Goel et al. (2). Similarly, the exclusion of all studies with
a high risk of bias in at least two domains (8,17,24–26)
did not cancel the beneﬁts observed in the ESI group (OR
1.75; 95% CI, 1.04–2.93; P< .03).VOL. 109 NO. 1 / JANUARY 2018
Fertility and Sterility®Secondary outcomes. The sensitivity analysis for all the
evaluated end points produced no changes in the comparison
between C-ESI and no treatment. A statistically signiﬁcant
increase in CPR of patients receiving P-ESI (OR 2.51; 95%
CI, 1.29–4.89; P¼ .007; I2 ¼ 0) was observed by excluding
Wadhwa et al. (25). No other change was found in the com-
parison P-ESI versus controls, and no modiﬁcations were ob-
tained from the singular exclusion of each study in the
comparison of P-ESI with C-ESI. The sensitivity analysis
based on study quality, when possible (due to the low number
of studies meta-analyzed for secondary outcomes), provided
no substantial changes to the results.
Pain and Complications
None of the studies quantitatively measured the patients’
discomfort during ESI (i.e., with a visual analogue scale),
and no information was reported about the potential short-
term or long-term complications. However, Wadhwa et al.
(25) mentioned that no patients receiving ESI treatment re-
ported experiencing severe pain or discomfort. Similarly,
Maged et al. (27) reported in the methods section that only
mild cramping similar to menstrual pain may be felt during
the scratch, and mild spotting may occur after withdrawal
of the catheter.
Overall Quality of Evidence
The overall quality of evidence was rated as low for CPR, OPR,
and MPR, and very low for MR and EPR (Table 2). The studies
were heterogeneous for ESI timing and methodology, as well
as for ovarian stimulation protocols. Moreover, several
studies were judged as being at unclear/high risk of selection
bias (2, 8, 26, 27), detection bias (8, 16, 25, 27), attrition bias
(24, 25), or reporting bias (15, 24, 25), which led us to
downgrade the cumulative evidence quality. Finally,
possible publication bias due to positive results and small
study effect was strongly suspected.
DISCUSSION
The real effectiveness of ESI in improving the reproductive
outcomes of patients undergoing ART is widely debated in
the literature. Some investigators consider the technique inef-
fective and prone to patient discomfort and a risk of Asher-
man's syndrome (10, 28, 29). Others have promoted its
effectiveness for improving the rate of embryo
implantation, with good tolerability and a low risk of
infectious events (27, 30, 31).
Beyond the open debate, a recent international survey
(12) performed across Australia, New Zealand, and the United
Kingdom demonstrated that ESI is broadly offered by infer-
tility care providers to patients undergoing ART. Nevertheless,
ESI recommendations generally are limited to women under-
going IVF, especially after repeated embryo-implantation
failures (recommended by 92% of physicians) (12, 32).
Indeed, only 3.6% of clinicians currently offer ESI to
patients before IUI, suggesting poor knowledge about the
beneﬁcial effects of ESI in such patients (12). The prior
systematic review investigating this topic (14) raised
uncertainties about the capability of ESI to improve CPRVOL. 109 NO. 1 / JANUARY 2018and OPR in women undergoing IUI or attempting to
conceive via sexual intercourse, but the results provided by
Lensen et al. (14) were affected by poor quality of evidence,
mainly due to high risk of bias in the included studies—the
investigators included data from meeting abstracts (33) and
data from an unpublished master's thesis (34)—and the high
degree of heterogeneity: only some patients received
ovarian stimulation, some patients attempting natural
conception (22), and others were undergoing IUI (24).
However, since the publication of the Lensen et al. review
(14) four additional RCTs have been published (2, 8, 15, 16).
Reports for this technique have doubled in last 2 years,
necessitating a new summary. We analyzed the impact of
ESI on the outcomes of patients undergoing IUI stimulated
cycles, based exclusively on data from RCTs.Main Findings
Eight RCTs (2,8,15,16,24–27) were included in our systematic
review, comprising a total of 1,871 IUI cycles (and 1,523
participants). In 998 IUI cycles the patients received ESI
(747 C-ESI and 251 P-ESI), and in 873 IUI cycles no
intervention was performed.
Effects of intervention on IUI outcomes. Concerning the
primary outcome (including both C-ESI and P-ESI in the
intervention group), the overall comparison between ESI
and controls showed statistically signiﬁcant advantages in
patients receiving ESI in terms of CPR (OR 2.27;
P< .00001; data from 1,871 IUI cycles) and OPR (OR 2.04
P¼ .004; data from 587 IUI cycles). Nevertheless, the body
of evidence was judged as moderate for CPR and as low
for OPR. In addition, ESI was not associated with a higher
risk of MPR (OR 1.09; P¼ .88), MR (OR 0.80; P¼ .60), or
EPR (OR 0.82; P¼ .80) in comparison with controls, even if
the quality of evidence was low (for MPR) or very low (for
MR and EPR).
Concerning the secondary outcomes, C-ESI was associ-
ated with a statistically signiﬁcantly higher CPR (OR 2.57;
P< .00001) and OPR (OR 2.27; P¼ .004) in comparison with
the controls. No advantage was shown for P-ESI in terms of
CPR (OR 1.75, P¼ .09, random effect model) or OPR (OR
1.47; P¼ .43), while the MPR, MR, and EPR (evaluated only
for C-ESI) did not substantially differ from those of the con-
trols. Finally, the comparison between C-ESI and P-ESI, based
on data from two studies (24, 25), showed no substantial
difference in terms of OPR, MPR, or MR (CPR and EPR were
not evaluable). However, the results of the comparison were
affected by the small number of participants included in the
analysis (n ¼ 250) and the two studies’ different
methodological concerns (24, 25).
The sensitivity analysis and the analysis of subgroups
produced no substantial modiﬁcations to the primary
outcome results, which conﬁrmed their robustness. The
exclusion of one study (25) from the comparison between
C-ESI and controls (secondary outcomes) produced a statisti-
cally signiﬁcant increase in the CPR of patients receiving P-
ESI (OR 2.51; P¼ .007), suggesting that the result was affected
by inconsistent data.93
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONPain and complications. No studies measured the patients’
pain (e.g., with a visual analogue scale) during the ESI proced-
ure. Only Wadhwa et al. (25) reported that no severe pain or
discomfort was experienced by patients receiving ESI, but
the investigators did not provide quantitative data. In this re-
gard, unpublished data from Mahey et al. (33) included in a
recent review (14) showed an average pain sensation
(measured with visual analogue scale) of 6/10 when a small
(no. 4) Karman cannula was used in the procedure. Thus,
even if pain related to ESI is not expected to be severe, this
aspect certainly needs further investigation.
In addition, no data about the short-term or long-term
complications of ESI were reported in the evaluated studies.
The literature lacks this information as well. The concerns
raised by some investigators about the potential risk of intra-
uterine adhesions after ESI should encourage future research
to counter such speculations.Implications
In spite of recent efforts in reproductive surgery (35, 36),
targeted drugs (37–39), preimplantation genetics (40), and
ovarian stimulation protocols (41, 42), the path from follicle
to ongoing pregnancy remains mysterious (43, 44) and
burdened by empiricism (45, 46). There is an absolute need
for novel, cost-effective, and evidence-based strategies to
improve the success of ART.
Endometrial scratch injury is a simple, low-cost proced-
ure (mean cost of 140 Australian dollars ¼ V95.1) (12) that
can be performed with a ﬂexible catheter, such as a Pipelle
(15). It does not require analgesia, and it can be performed
as part of an outpatient regimen (2, 12). The rationale of
administering a voluntary endometrial trauma is to induce
the local release of cytokines (such as interleukin 6 and 11),
growth-factors (including tumor necrosis factor-a and am-
phiregulin), and enzymes and adhesion molecules (such as
laminin a4, integrin a6, matrix metalloproteinase 1, and gly-
codelin A) (2, 15). The acute inﬂammatory process creates an
angiogenic environment, which may promote embryo-
uterine crosstalk and result in successful implantation (16,
27). According to various investigators, ESI may mitigate
the detrimental effects of ovarian stimulation of the
endometrium and favor endometrial and embryo
synchronization (47, 48).
The inﬂammatory theory may provide a physiological
explanation of the beneﬁts of ESI observed in our meta-
analysis. However, at present it is still an intriguing hypoth-
esis that has yet to be conﬁrmed by evidence from histologic
studies. Nevertheless, the recent literature has suggested that
endometrial inﬂammation, especially if chronic, may be
detrimental for embryo implantation and development,
potentially leading to female infertility and recurrent preg-
nancy loss (49–51). Thus, the true physiological and
biochemical rationale of ESI's effect on embryo-uterine cross-
talk still needs to be elucidated, and solid evidence is needed
to draw any conclusions about the beneﬁts of driven inﬂam-
mation on implantation. In fact, using ESI resulted in no
advantage in terms of CPR or OPR in the study with the great-
est weight (according to our study quality judgment) (26). It94was probably due a lack of beneﬁts from follicular P-ESI
(days 6–8 of the cycle preceding IUI) or perhaps to a more
vigorous endometrial injury inﬂicted by the use of a Novak
curette.
Strengths and Limitations
Originality, strict inclusion criteria, and rigorous methodol-
ogy represent points of strength of the present review. We
selected only RCTs with women undergoing IUI stimulated
cycles with the aim of reducing the bias related to heterogene-
ity in study designs, population characteristics, and type of
IUI cycles (stimulated/not stimulated). Moreover, the low sta-
tistical heterogeneity detected between the studies (I2 ¼ 0)
represents a further point of strength of our meta-analysis,
supporting the substantial consistency of our ﬁndings.
However, the present study is not exempt from limita-
tions. First, we performed a meta-analysis exclusively on
published data. This exposes our ﬁndings to the considerable
risk of publication bias, which potentially affects their reli-
ability. Moreover, a moderate degree of heterogeneity within
the studies was present in terms of patients’ characteristics
(percentages of different reproductive disorders), ESI timing
and technique (different tools), ovarian stimulation protocols
(drugs administered and criteria for ovulation induction), and
methodological quality. Such factors may potentially repre-
sent additional sources of bias in our ﬁnal statements.
CONCLUSION
We found poor evidence quality (GRADE of evidence: low) that
ESI improves CPR (OR 2.27, P< .00001) and OPR (OR 2.04,
P¼ .004) in patients undergoing IUI without increasing the
risk of multiple pregnancy, miscarriage, or ectopic pregnancy
(GRADE score: low/very low). However, the evidence in favor
of performing ESI once during the follicular phase of the
same cycle of IUI with a ﬂexible aspiration catheter appears
to be promising. Conversely, performing P-ESI is supported
by inconsistent evidence, as is using other biopsy devices.
Moreover, ESI is expected to be safe, although clear evidence
about its short-term and long-term complications is warranted.
Similarly, few data are available concerning the pain experi-
enced during ESI, which requires future research.
We believe our efforts should be of great interest to the
scientiﬁc community because of their direct implications for
the clinical practice of fertility care providers. Our results sup-
port clinicians by providing an updated summary on ESI use
in IUI and advising about the uncertainties in the real chances
of ESI improving CPR and OPR. Despite the novel evidence
provided by our study, there is still a need for further robust,
high-quality RCTs to conﬁrm the effectiveness and safety ESI
before routinely recommending its use in patients undergoing
IUI cycles.
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SUPPLEMENTAL FIGURE 2
Risk of bias graph. The authors' judgment about each risk of bias item presented as percentages across the included studies.
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Endometrial scratch in the preceding cycle versus no intervention: clinical pregnancy rate.
Vitagliano. Endometrial scratching and insemination. Fertil Steril 2017.
VOL. 109 NO. 1 / JANUARY 2018 96.e3
Fertility and Sterility®
SUPPLEMENTAL FIGURE 4
Endometrial scratch in the same cycle versus endometrial scratch in the preceding cycle: clinical pregnancy rate.
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